Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Sanara MedTech (SMTI) over the last 7 years, with Q3 2025 value amounting to $656386.0.

  • Sanara MedTech's Non-cash Items rose 1988.12% to $656386.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $656386.0, marking a year-over-year increase of 1988.12%. This contributed to the annual value of $31013.0 for FY2024, which is 6696.95% down from last year.
  • Latest data reveals that Sanara MedTech reported Non-cash Items of $656386.0 as of Q3 2025, which was up 1988.12% from $552803.0 recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Non-cash Items ranged from a high of $2.4 million in Q1 2024 and a low of $11500.0 during Q1 2021
  • Moreover, its 5-year median value for Non-cash Items was $110032.0 (2023), whereas its average is $291761.2.
  • Examining YoY changes over the last 5 years, Sanara MedTech's Non-cash Items showed a top increase of 168248.8% in 2025 and a maximum decrease of 9872.8% in 2025.
  • Over the past 5 years, Sanara MedTech's Non-cash Items (Quarter) stood at $11500.0 in 2021, then skyrocketed by 1171.23% to $146191.0 in 2022, then crashed by 35.77% to $93892.0 in 2023, then crashed by 66.97% to $31013.0 in 2024, then skyrocketed by 2016.49% to $656386.0 in 2025.
  • Its Non-cash Items was $656386.0 in Q3 2025, compared to $552803.0 in Q2 2025 and $31013.0 in Q1 2025.